Robert Kamen - Jun 18, 2021 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Director
Signature
/s/ Caroline Gammill, Attorney-in-fact
Stock symbol
JNCE
Transactions as of
Jun 18, 2021
Transactions value $
$0
Form type
4
Date filed
6/22/2021, 04:49 PM
Next filing
Jun 28, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +15.7K $0.00 15.7K Jun 18, 2021 Common Stock 15.7K $7.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.

Remarks:

Exhibit 24 - Limited Power of Attorney